A New Dermatology Review on HRT and Skin Arrives Just as the FDA Erases Its Warning Label

A paper scheduled for the October 2026 issue of the Journal of the American Academy of Dermatology, authored by Diala Haykal and published by Elsevier, examines what recent regulatory changes to hormone replacement therapy mean for menopausal skin aging. The timing is notable: the paper follows a major shift in how U.S. regulators frame HRT's risk profile, and its publication date places it squarely after the policy change rather than as a response built on years of new clinical data.

In November 2025, the FDA announced it would remove the black box warning that had accompanied hormone therapy products for more than two decades, covering risks such as breast cancer, heart attack and stroke, according to the FDA's own press announcement. Health and Human Services Secretary Robert F. Kennedy Jr. framed the decision as a matter of scientific correction, saying it "reflects our commitment to follow the science wherever it leads and to correct course when the evidence demands it," as reported by CancerNetwork. The changes, expected within six months of the announcement, will introduce age-specific labeling, according to Harvard Health.

The regulatory shift matters for dermatology because it may accelerate prescribing and marketing of HRT for skin-related complaints, even though the clinical evidence for that specific use has not changed. A 2025 narrative review in the Journal of Cosmetic Dermatology, led by Viscomi and colleagues, states plainly that despite decades of research, "clinical guidelines do not support HRT use solely for estrogen-deficient skin due to a lack of robust clinical trials," according to the paper published in Wiley Online Library. That review also notes that most supportive findings come from early, small studies linking HRT to improved skin parameters, not from the large randomized trials that would be needed to establish a dermatologic indication.

This gap between regulatory momentum and trial-level evidence is not new. A 1997 study published in Maturitas, cited in an older ScienceDirect commentary on hormone therapy and skin aging, found that systemic estrogen or estrogen-progestin therapy had no measurable effect on skin collagen in postmenopausal women, according to ScienceDirect. Nearly three decades later, a short review published in the Global Research and Evolving Medicine journal in 2024 still describes the overall picture in probabilistic terms, noting that "the great majority of studies showed interesting associations between improved skin physical parameters and hormone replacement," language that signals correlation rather than the kind of causal, dose-controlled data regulators would typically require for an approved skin indication, per GREM Journal.

Not every voice in the current debate is aligned with the FDA's framing. Coverage in the American Journal of Managed Care notes that some experts caution against overstating HRT's benefits, particularly for women with a history of breast cancer, according to AJMC. Harvard Health likewise emphasizes that women should still discuss individual risk factors, such as prior heart attack, stroke or blood clots, with their physicians before starting therapy, per its patient guidance page.

What the Haykal paper adds to this landscape is less a new clinical trial than a synthesis written at a moment when the regulatory ground has shifted beneath the existing evidence base. Readers evaluating its claims about skin aging benefits will need to look closely at what kind of studies it cites, whether randomized controlled trials, observational cohorts, or the small mechanistic studies that dominated the field in the 1990s, because the label change itself supplies no new data about collagen, elasticity or wound healing. The FDA's November 2025 announcement changed what a prescription bottle will say. It did not change what the underlying trials, some dating back to 1997, actually measured.